We Can Edit Genes Now. Let That Sink In.
In December 2023, the FDA approved Casgevy — the first CRISPR-based gene therapy. It literally edits your DNA to cure sickle cell disease. One treatment. Permanent cure. No more managing symptoms for life.
That approval wasn't a scientific curiosity — it was a starting gun. The gene therapy market is projected to reach $500 billion by 2032. We're not talking about incremental drug improvements. We're talking about curing diseases at their genetic root. Cancer, blindness, muscular dystrophy, hemophilia, heart disease — all have gene therapy programs in clinical trials right now.
The Technology Stack
CRISPR Gene Editing
CRISPR-Cas9 is the "find and replace" for DNA. It can cut, delete, or insert specific gene sequences with precision that was science fiction 15 years ago. The technology earned Jennifer Doudna and Emmanuelle Charpentier a Nobel Prize in 2020.
Gene Replacement Therapy
Instead of editing existing genes, these therapies deliver working copies of defective genes using viral vectors (harmless viruses that carry the correct DNA into cells). Luxturna ($850K per treatment) restores vision in genetic blindness. Zolgensma ($2.1M) treats spinal muscular atrophy in infants.
mRNA Technology
COVID vaccines proved mRNA works at scale. Now Moderna and BioNTech are using the same platform for cancer vaccines, rare diseases, and autoimmune conditions. mRNA tells your cells to produce therapeutic proteins — no gene editing required.
Cell Therapy
CAR-T therapy modifies your own immune cells to attack cancer. Already approved for several blood cancers with 50-80% complete remission rates in patients who had no other options. Companies are now working on solid tumor applications.
The Companies to Watch
- CRISPR Therapeutics (CRSP): Co-developed Casgevy. Pipeline includes cancer immunotherapies and diabetes cure programs. The flagship CRISPR investment.
- Intellia Therapeutics (NTLA): In-vivo CRISPR (editing genes inside the body, not in a lab). Lead program for transthyretin amyloidosis showed stunning Phase 2 results.
- Editas Medicine (EDIT): First CRISPR company to dose patients. Focus on genetic eye diseases and cancer.
- Moderna (MRNA): Beyond COVID — personalized cancer vaccines showing remarkable Phase 3 results. mRNA flu vaccines. RSV vaccines. The platform is the product.
- BioNTech (BNTX): mRNA cancer vaccines in partnership with Roche/Genentech. Potentially curative treatments for melanoma and pancreatic cancer.
- Vertex Pharmaceuticals (VRTX): Partner on Casgevy. Pipeline in pain, kidney disease, and Type 1 diabetes. Strong revenue base from CF drugs funds speculative pipeline.
- Beam Therapeutics (BEAM): "Base editing" — more precise than standard CRISPR. Can change individual DNA letters without cutting the double helix. Next-generation gene editing.
How to Build a Biotech Portfolio
- ETF approach (lower risk): XBI (SPDR S&P Biotech ETF) or ARKG (ARK Genomic Revolution ETF) for broad exposure
- Picks approach: Core positions in Vertex + Moderna (established revenue) with smaller positions in CRISPR Therapeutics and Intellia (higher growth potential)
- Risk management: Biotech is binary — clinical trials either succeed or fail. Never put more than 5-10% of portfolio in individual biotech stocks. Diversify across multiple therapeutic approaches.
We're living through a moment comparable to the invention of antibiotics. Gene therapy will eventually cure thousands of genetic diseases. The investment opportunity mirrors early-stage internet investing — volatile, uncertain, but with potential returns that justify the risk for patient capital.
